scholarly journals A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Sven Jungmann ◽  
Wolf-Dieter Ludwig ◽  
Nicolas Schönfeld ◽  
Torsten-Gerriet Blum ◽  
Claudia Großwendt ◽  
...  
Keyword(s):  
Side Effects ◽  
Lung Disease ◽  
Interstitial Pneumonia ◽  
Early Stage ◽  
Case Reports ◽  
Individual Case ◽  
Close Monitoring ◽  
Non Hodgkin Lymphoma ◽  
First Case ◽  
Nonspecific Interstitial Pneumonia

We present a 74-year-old male with nonspecific interstitial pneumonia (NSIP) during treatment with ibrutinib for mantle cell lymphoma. Previously, the patient had received six cycles of bendamustine and rituximab and six cycles of R-CHOP, followed by rituximab maintenance therapy. Respiratory tract complications of ibrutinib other than infectious pneumonia have not been mentioned in larger trials, but individual case reports hinted to a possible association with the development of pneumonitis. In our patient, the onset of alveolitis that progressed towards NSIP together with the onset of ibrutinib treatment suggests causality. One week after ibrutinib was discontinued, nasal symptoms resolved first. A follow-up CT showed a reduction in the reticular hyperdensities and ground-glass opacities, suggestive of restitution of the lung disease. To our knowledge, this is the first case showing a strong link between ibrutinib and interstitial lung disease, strengthening a previous report on subacute pneumonitis. Our findings have clinical implications because pulmonary side effects were reversible at this early stage. We, therefore, suggest close monitoring for respiratory side effects in patients receiving ibrutinib.

The Use of Methylphenidate for Cognitive Decline Associated with HIV Disease

1995 ◽  
Vol 25 (1) ◽  
pp. 21-37 ◽  
Author(s):  
George R. Brown
Keyword(s):  
Side Effects ◽  
Hiv Infection ◽  
Early Stage ◽  
Case Reports ◽  
English Literature ◽  
Pharmacokinetic Data ◽  
Hiv Disease ◽  
Cognitive Changes ◽  
Persons Living With Hiv ◽  
Hiv Aids

Objective: Complaints of cognitive changes are often expressed by patients at all stages of HIV infection. Such changes include decreased memory and attention span, diminished concentration, apathy, and “slowing.” Methylphenidate (MPD) has been used in several clinical studies in men with late-stage HIV disease in an attempt to ameliorate these difficulties. The objectives of this review article are to review salient psychopharmacological characteristics of MPD and to describe the research and clinical literature supporting the use of MPD in patients at all stages of HIV infection. Methods: Seven studies, case reports, or abstracts from International Conferences on AIDS were available in the English literature through August, 1993, directly addressing the use of MPD in patients with HIV disease. Twenty-nine papers were reviewed for pharmacokinetic data, eighteen for safety and side effects issues, and seventeen for relevant contributions from the neuropsychological testing literature. Results: Studies in clinical settings have used doses ranges from 10–90 mg. per day in two or three divided doses with reportedly good results in improving both affective and cognitive symptoms associated with HIV disease. Side effects have been relatively mild and patient satisfaction with treatment has been high. However, no studies have been conducted in early stage HIV disease, where a significant minority of patients have similar complaints in the absence of clinically apparent immunosuppression. Likewise, placebo-controlled, dose-finding studies in AIDS patients are entirely lacking, and no studies in women with HIV disease and cognitive changes have been published. Conclusions: In spite of these important research shortcomings, clinical experience with MPD treatment of cognitive changes in men with HIV/AIDS is consistent with the notion that this medication holds significant promise to improve the quality of life for persons living with HIV/AIDS. Controlled studies to test this hypothesis are warranted.

scholarly journals Radiological diagnosis of interstitial lung diseases

2013 ◽  
Vol 66 (suppl. 1) ◽  
pp. 29-33
Author(s):  
Ruza Stevic ◽  
Vucinic Mihailovic ◽  
Dragana Jovanovic ◽  
Nada Vasic
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Interstitial Pneumonia ◽  
Lung Diseases ◽  
Usual Interstitial Pneumonia ◽  
Interstitial Lung Diseases ◽  
Ground Glass ◽  
Cryptogenic Organizing Pneumonia ◽  
Acute Interstitial Pneumonia ◽  
Nonspecific Interstitial Pneumonia

Introduction. Interstitial lung diseases include the entities of idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, desquamative interstitial pneumonia, and lymphocytic interstitial pneumonia. Recent introduction of high-resolution computed tomography has made the diagnosis of interstitial lung disease much easier. Usual interstitial pneumonia A predominantly subpleural reticulation and honeycombing at the basal posterior part of the lung with a progression to anterior and superior parts are characteristic of usual interstitial pneumonia/ idiopathic pulmonary fibrosis. Nonspecific interstitial pneumonia Typical findings of nonspecific interstitial pneumonia are bilateral, relatively symmetrical subpleural ground glass opacifications and irregular linear opacities. Desquamative interstitial pneumonia is characterized by diffuse symmetrical ground glass opacifications. Respiratory bronchiolitisassociated interstitial lung disease Centrilobular nodules and irregular ground glass opacifications are present. Cryptogenic organizing pneumonia Subpleural and peribronchial consolidations are prominent findings that are not present in other idiopathic interstitial pneumonias. Acute interstitial pneumonia. Bilateral ground-glass opacifications are present and areas of peripheral consolidations may also be seen in acute interstitial pneumonia. Lymphocytic interstitial pneumonia. Diffuse or patchy areas of ground glass opacification with centrilobular nodules and occasionally well-defined cysts are seen. Conclusion. Imaging plays a crucial role in identifying interstitial lung diseases but precise diagnosis requires a dynamic interdisciplinary approach that correlates clinical, radiological and pathologic features.

scholarly journals De novo AVM formation following venous sinus thrombosis and prior AVM resection in adults: report of 2 cases

2018 ◽  
Vol 128 (2) ◽  
pp. 506-510 ◽  
Author(s):  
Siyu Shi ◽  
Raghav Gupta ◽  
Justin M. Moore ◽  
Christoph J. Griessenauer ◽  
Nimer Adeeb ◽  
...  
Keyword(s):  
De Novo ◽  
Sinus Thrombosis ◽  
Case Reports ◽  
Individual Case ◽  
Postnatal Period ◽  
Adult Patients ◽  
Venous Sinus ◽  
Venous Sinus Thrombosis ◽  
First Case ◽  
Congenital Origin

Brain arteriovenous malformations (AVMs) are traditionally considered congenital lesions, arising from aberrant vascular development during the intrauterine period. Rarely, however, AVMs develop in the postnatal period. Individual case reports of de novo AVM formation in both pediatric and adult patients have challenged the traditional dogma of a congenital origin. Instead, for these cases, a dynamic picture is emerging of AVM growth and development, initially triggered by ischemic and/or traumatic events, coupled with genetic predispositions. A number of pathophysiological descriptions involving aberrant angiogenic responses following trauma, hemorrhage, or inflammation have been proposed, although the exact etiology of these lesions remains to be elucidated. Here, the authors present 2 cases of de novo AVM formation in adult patients. The first case involves the development of an AVM following a venous sinus thrombosis and to the authors' knowledge is the first of its kind to be reported in the literature. They also present a case in which an elderly patient with a previously ruptured AVM developed a second AVM in the contralateral hemisphere 11 years later. In addition to presenting these cases, the authors propose a possible mechanism for de novo AVM development in adult patients following ischemic injury.

scholarly journals A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia

2019 ◽  
Vol 51 (3) ◽  
pp. 306-309
Author(s):  
Jee-Soo Lee ◽  
Ho Young Kim ◽  
Miyoung Kim ◽  
Young Kyung Lee
Keyword(s):  
Essential Thrombocythemia ◽  
Frameshift Mutation ◽  
Myeloproliferative Neoplasms ◽  
Case Reports ◽  
Individual Case ◽  
First Case ◽  
Exon 9 ◽  
Calr Mutations

Abstract The clinical phenotypes and prognoses of CALR-mutant myeloproliferative neoplasms depend on the mutation type. The 2 most common mutations, type 1 (52-bp deletion) and type 2 (5-bp insertion), account for 85% of CALR-mutated neoplasms. The former confers a myelofibrotic phenotype, and the latter is associated with a low risk of thrombosis and an indolent clinical course. Individual case reports for patients with novel pathogenic CALR mutations are rare. Herein, we present the first case in the literature, to our knowledge, of a 63-year old ethnic Korean man with essential thrombocythemia who was diagnosed with a novel +1-bp frameshift mutation in CALR, which was predicted to exhibit a type 2–like phenotype.

scholarly journals A HIDDEN DIAGNOSIS MANIFESTING AS NONSPECIFIC INTERSTITIAL PNEUMONIA: IGG4-RELATED LUNG DISEASE

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A2010-A2011
Author(s):  
Hema Balina ◽  
Kevin Dsouza ◽  
Pilar Acosta Lara ◽  
Tracy Luckhardt ◽  
Tejaswini Kulkarni ◽  
...  
Keyword(s):  
Lung Disease ◽  
Interstitial Pneumonia ◽  
Nonspecific Interstitial Pneumonia

CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia

Radiology ◽  
2004 ◽  
Vol 232 (2) ◽  
pp. 560-567 ◽  
Author(s):  
Sujal R. Desai ◽  
Srihari Veeraraghavan ◽  
David M. Hansell ◽  
Ageliki Nikolakopolou ◽  
Nicole S. L. Goh ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Interstitial Pneumonia ◽  
Nonspecific Interstitial Pneumonia ◽  
Ct Features

A rare association of leiomyosarcoma with squamous cell carcinoma of the larynx: two cases

2013 ◽  
Vol 127 (8) ◽  
pp. 828-831 ◽  
Author(s):  
E Kara ◽  
M F Cetik ◽  
U Tuncer ◽  
A Uguz
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Early Stage ◽  
Case Reports ◽  
Primary Tumour ◽  
Partial Laryngectomy ◽  
Adequate Treatment ◽  
Treatment Choices ◽  
First Case

AbstractObjective:To discuss the histopathogenesis and treatment choices for synchronous tumours of the larynx.Case reports:We present two cases of synchronous laryngeal leiomyosarcoma and squamous cell carcinoma. The first case was an early-stage tumour and the second an advanced-stage tumour of the larynx. Selection of adequate treatment for synchronous tumours is difficult because of different spreading rates and metastatic patterns. Treatment choices for both the primary tumour site and the neck should be related to the stage of the squamous component of the tumour.Conclusion:In such cases, the tumour location, tumour stage and lymphatic metastases must be carefully evaluated in order to make the optimum treatment choice. Treatment evaluation of the neck should be related to the stage of the squamous component of these synchronous tumours. Partial laryngectomy techniques may be preferred if the extent of the disease permits.

scholarly journals Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports

2020 ◽  
Author(s):  
Guiomar Pinheiro ◽  
Ana Rita Costa ◽  
Ana Campar ◽  
Teresa Mendonça
Keyword(s):  
Side Effects ◽  
Partial Response ◽  
Adverse Effects ◽  
Large Scale ◽  
Case Reports ◽  
Immunosuppressive Drugs ◽  
Systemic Corticosteroids ◽  
First Case ◽  
Symptom Relapse

Fasciitis with eosinophilia (FE) is a rare connective tissue disease. Due to its rarity, large-scale studies are lacking, which makes its treatment challenging. Systemic corticosteroids (SCSs) are the cornerstone of treatment; however, additional immunosuppressive drugs (ISDs) are frequently necessary (usually methotrexate). We report 2 patients, for whom an SCS and methotrexate were not a viable long-term option. In the first case, we were unable to taper the SCS dose without symptom relapse, the patient showed only a partial response to methotrexate and presented side effects. The second case never fully responded to the SCS and methotrexate and demonstrated serious SCS adverse effects. Both patients were started on tocilizumab with extremely favourable results, making this drug a potential therapeutic weapon for these patients.

Sign in / Sign up

Export Citation Format

Share Document